MicroRNA-302a/d inhibits the self-renewal capability and cell cycle entry of liver cancer stem cells by targeting the E2F7/AKT axis

Ma, Yu‐Shui; Lv, Zhongwei; Yu, Fei; Chang, Zhengyan; Cong, Xianling; Zhong, Xiaoming; Lu, Gai‐Xia; Zhu, Jian; Fu, Da

doi:10.1186/s13046-018-0927-8

Cited by 65 publications

(57 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, tumor cell differentiation is modulated by the apparent downregulation of miR‐302b in ESCC . One study on HCC showed that the E2F7/AKT/β‐catenin/CCND1 pathway is regulated by miR‐302a/d, which can inhibit the stemness of liver CSCs and the proliferation of tumor cells . Furthermore, some evidence from a glioblastoma mouse model showed that the cell‐to‐cell transfer of miR‐302/367 can result in the inhibition of CXCR4/SDF1, SHH, CCND, CCNA and E2F1, which are targets of miR‐302/367 …”

Section: Regulatory Role and Mechanisms Of Mir‐302/367 Cluster Regardmentioning

confidence: 99%

Application of the microRNA‐302/367 cluster in cancer therapy

Liu

Wang

et al. 2020

Cancer Science

View full text Add to dashboard Cite

This is an open access article under the terms of the Creat ive Commo ns Attri butio n-NonCo mmerc ial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. , glycogen synthase kinase-3β; HCC, hepatocellular carcinoma; HECC, human endometrial carcinoma cell; hESC, human embryonic stem cell; IGF-1R, insulin-like growth factor 1 receptor; iPSCs, induced pluripotent stem cells; JNK, c-Jun NH2-terminal kinase; KLF4, Kruppel Like Factor 4; KPNA2, NF-κB-inducing kinase and karyopherin α2; LATS2, large tumor suppressor kinase 2; lncRNA, long noncoding RNA; LSCC, laryngeal squamous cell carcinoma; Mcl-1, myeloid cell leukemia sequence 1; MIAT, myocardial infarction-associated transcript; miRNA, microRNA; mirPS, miRNA-induced pluripotent stem; MTDH, metadherin; ncRNA, noncoding RNA; NK, natural killer; Notch4, notch receptor 4; NR2F2, nuclear receptor subfamily 2 group F member 2; OC, ovarian cancer; OCT, organic cation/carnitine transporter; PCa, prostate cancer; P-gp, P-glycoprotein; PRP-1, proline-rich polypeptide 1; RACK1, receptor for activated C-kinase 1; S1pr1, sphingosine-1-phosphate receptor 1; SDC1, syndecan 1; SDF1, stromal cell-derived factor 1; SHH, sonic hedgehog; SOX2, SRY-box transcription factor 2; Tcf3, transcription factor 3; SSEA-4, stage-specific embryonic antigen-4; YAP, Yes-associated transcriptional regulator. AbstractAs a novel class of noncoding RNAs, microRNAs (miRNAs) can effectively silence their target genes at the posttranscriptional level. Various biological processes, such as cell proliferation, differentiation, and motility, are regulated by miRNAs. In different diseases and different stages of disease, miRNAs have various expression patterns, which makes them candidate prognostic markers and therapeutic targets.Abnormal miRNA expression has been detected in numerous neoplastic diseases in humans, which indicates the potential role of miRNAs in tumorigenesis. Previous studies have indicated that miRNAs are involved in nearly the entire process of tumor development. MicroRNA-302a, miR-302b, miR-302c, miR-302d, and miR-367 are members of the miR-302/367 cluster that plays various biological roles in diverse neoplastic diseases by targeting different genes. These miRNAs have been implicated in several unique characteristics of cancer, including the evasion of growth suppressors, the sustained activation of proliferative signaling, the evasion of cell death and senescence, and the regulation of angiogenesis, invasion, and metastasis.This review provides a critical overview of miR-302/367 cluster dysregulation and the subsequent effects in cancer and highlights the vast potential of members of this cluster as therapeutic targets and novel biomarkers. K E Y W O R D Sbiological phenomena, cell dedifferentiation, MIRN302, neoplasm, therapy

show abstract

Section: Regulatory Role and Mechanisms Of Mir‐302/367 Cluster Regardmentioning

confidence: 99%

Application of the microRNA‐302/367 cluster in cancer therapy

Liu

Wang

et al. 2020

Cancer Science

View full text Add to dashboard Cite

show abstract

“…miR-302a/d binds to the 3'UTR of E2F7 mRNA and inhibits its translation. The induced miR-302a/d expression in CSCs attenuates the stemness through indirect downregulation of the Akt/β-catenin/cyclin D1 pathway, suggesting miR-302a/d is a potential biomarker in HCC stem cell therapy via targeting of E2F7 [131].…”

Section: Mir-302a/dmentioning

confidence: 99%

microRNA: The Impact on Cancer Stemness and Therapeutic Resistance

Jiao

Qian

et al. 2019

Cells

View full text Add to dashboard Cite

Cancer ranks as the second leading cause of death worldwide, causing a large social and economic burden. However, most anti-cancer treatments face the problems of tumor recurrence and metastasis. Therefore, finding an effective cure for cancer needs to be solved urgently. Recently, the discovery of cancer stem cells (CSCs) provides a new orientation for cancer research and therapy. CSCs share main characteristics with stem cells and are able to generate an entire tumor. Besides, CSCs usually escape from current anti-cancer therapies, which is partly responsible for tumor recurrence and poor prognosis. microRNAs (miRNAs) belong to small noncoding RNA and regulate gene post-transcriptional expression. The dysregulation of miRNAs leads to plenty of diseases, including cancer. The aberrant miRNA expression in CSCs enhances stemness maintenance. In this review, we summarize the role of miRNAs on CSCs in the eight most common cancers, hoping to bridge the research of miRNAs and CSCs with clinical applications. We found that miRNAs can act as tumor promoter or suppressor. The dysregulation of miRNAs enhances cell stemness and contributes to tumor metastasis and therapeutic resistance via the formation of feedback loops and constitutive activation of carcinogenic signaling pathways. More importantly, some miRNAs may be potential targets for diagnosis, prognosis, and cancer treatments.

show abstract

“…E2F7 was found to be upregulated in many types of neoplasms, like endometrial cancer (Q. Li et al, 2015) and non‐small‐cell lung cancer (Wang, Li, Xu, Niu, & Li, 2019). But the roles it plays are controversial in different cancer types, for example, it may serve as a protective factor in cutaneous squamous cell carcinoma (Thurlings et al, 2017), or risk factor in hepatocellular carcinoma (HCC; Ma et al, 2018) and lung adenocarcinoma (LUAD; Liang et al, 2018). Therefore, we questioned the mechanism and clinical significance of E2F7 in READ development.…”

Section: Introductionmentioning

confidence: 99%

miR‐129‐5p inhibits proliferation, migration, and invasion in rectal adenocarcinoma cells through targeting E2F7

Wan

Bai

Yang

et al. 2020

Journal Cellular Physiology

View full text Add to dashboard Cite

microRNAs (miRNAs), a kind of small noncoding RNAs, are considered able to regulate expression of genes and mediate RNA silencing. miR‐129‐5p was shown to be a cancer‐related miRNA. However, the influence of miR‐129‐5p in rectal adenocarcinoma (READ) development remains to be determined. Based on the TCGA data, downregulation of miR‐129‐5p in READ samples was observed. Manual restoration of the miR‐129‐5p in SW1463 and SW480 cell lines significantly inhibited invasion, migration, and proliferation of READ cell lines, while the apoptosis ability was enhanced. Meanwhile, we found E2F7 acted as a potential target of miR‐129‐5p and was upregulated in READ samples. E2F7 upregulation reversed the repression of miR‐129‐5p on READ development. Finally, in vivo experiments showed that inhibition of tumor growth in nude mice was achieved through upregulating miR‐129‐5p. Overall, our findings suggest increasing of miR‐129‐5p leads to the suppression of READ progression through regulating the expression of E2F7, which may provide novel insights into the treatment of READ.

show abstract

MicroRNA-302a/d inhibits the self-renewal capability and cell cycle entry of liver cancer stem cells by targeting the E2F7/AKT axis

Cited by 65 publications

References 56 publications

Application of the microRNA‐302/367 cluster in cancer therapy

Application of the microRNA‐302/367 cluster in cancer therapy

microRNA: The Impact on Cancer Stemness and Therapeutic Resistance

miR‐129‐5p inhibits proliferation, migration, and invasion in rectal adenocarcinoma cells through targeting E2F7

Contact Info

Product

Resources

About